European Heart Journal

European Heart Journal 2000 21(23):1944-1953; doi:10.1053/euhj.2000.2243
Copyright © 2000 by the European Society of Cardiology.

This Article Abstract FREE Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (67) Request Permissions Disclaimer Google Scholar Articles by Antman, E.M Articles by Braunwald, E Search for Related Content PubMed PubMed Citation Articles by Antman, E.M Articles by Braunwald, E Social Bookmarking          What's this?

Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14

E.M Antman^a,f1, C.M Gibson^b, J.A de Lemos^a, R.P Giugliano^a, C.H McCabe^a, P Coussement^c, I Menown^d, C.A Nienaber^e, T.C Rehders^e, M.J Frey^f, R Van der Wieken^g, D Andresen^h, J Schererⁱ, K Anderson^j, F Van de Werf^c and E Braunwald^a

^a Brigham and Women's Hospital, Boston, MA, U.S.A.
^b University of California, San Francisco, CA, U.S.A.
^c Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
^d Royal Victoria Hospital, Belfast, U.K.
^e University Hospital Eppendorf, Hamburg, Germany
^f Sarasota Memorial Hospital, Sarasota, FL, U.S.A.
^g OLVG afdeling Cardiologie, Amsterdam, The Netherlands
^h Krankenhaus am Urban, Berlin, Germany
ⁱ Eli Lilly, Inc. Indianapolis, IN, U.S.A.
^j Centocor, Malvern, PA, U.S.A.

Received April 18, 2000; accepted April 19, 2000

Abstract

Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combination with a reduced dose of reteplase for ST-elevation myocardial infarction.

Methods and Results Patients (n=299) with ST-elevation myocardial infarction were treated with aspirin and randomized to a control arm with standard dose reteplase (10+10U given 30min apart) or abciximab (bolus of 0·25mg.kg^–1and 12-h infusion of 0·125µg.kg^–1.min^–1) in combination with reduced doses of reteplase (5+5U or 10+5U). Control patients received standard weight-adjusted heparin (bolus of 70U.kg^–1; infusion of 15U.kg^–1.h^–1), while each of the combination arms with abciximab and reduced dose reteplase received either low dose heparin (bolus of 60U.kg^–1; infusion of 7U.kg^–1.h^–1) or very low dose heparin (bolus of 30U.kg^–1; infusion of 4U.kg^–1.h^–1). The rate of TIMI 3 flow at 90min was 70% for patients treated with 10+10U of reteplase alone (n=87), 73% for those treated with 5+5U of reteplase with abciximab (n=88), and 77% for those treated with 10+5U of reteplase with abciximab (n=75). Complete (70%) ST resolution at 90min was seen in 56% of patients receiving a reduced dose of reteplase in combination with abciximab compared with 48% of patients receiving reteplase alone.

Conclusions Reduced doses of reteplase when administered in combination with abciximab were associated with higher TIMI 3 flow rates than reported previously for reduced doses of reteplase without abciximab and were at least as high as for full dose reteplase alone

Key Words: Thrombolysis, acute MI, glycoprotein IIb/IIIa inhibition, antiplatelet therapy

^f1 Correspondence: Elliott M. Antman, MD., Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, U.S.A.

References

1. Antman EM, Giugliano RP, Gibson CM. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]
2. de Lemos JA, Antman EM, Gibson CM. Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST Elevation Myocardial Infarction: Observations from the TIMI 14 Trial. Circulation. 2000;101:239–243[Abstract/Free Full Text]
3. Smalling RW, Bode C, Kalbafleisch J. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995;91:2725–2732[Abstract/Free Full Text]
4. Bode C, Smalling RW, Berg G. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891–898[Abstract/Free Full Text]
5. Chesebro JH, Knatterud G, Roberts R. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142–154[Abstract/Free Full Text]
6. Gibson CM, Cannon CP, Daley WL. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–888[Abstract/Free Full Text]
7. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 1996;94:911–921[Abstract/Free Full Text]
8. Cannon CP, McCabe CH, Henry TD. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23:993–1003[Abstract]
9. deLemos JA, Antman EM, Giugliano RP. ST-segment resolution and infarct related artery patency and flow after thombolytic therapy. Am J Cardiol. 2000;85:299–304[CrossRef][Web of Science][Medline]
10. Schröder R, Dissmann R, Bruggemann T. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384–391[Abstract]
11. Schröder R, Wegscheider K, Schröder K. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: a substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol. 1995;26:1657–1664[Abstract]
12. Gibson CM, Cannon CP, Murphy SA. Relationship of TIMI myocardial perfusion grade to mortality following thrombolytic administration. Circulation. 2000;101:125–130[Abstract/Free Full Text]
13. Wald, A. Sequential Analysis, Dover Publications, 1947, 88, 105
14. Gibson CM, Murphy S, Menown IBA. Determinants of coronary blood flowing following thombolytic administration. J Am Coll Cardiol. 1999;34:1403–1412[Abstract/Free Full Text]
15. Coulter SA, Cannon CP, Ault KA. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (Thrombolysis in Myocardial Infarction) 14. Circulation. 2000;101:2690–2695[Abstract/Free Full Text]
16. Carr ME Jr, Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost. 1995;73:499–505[Web of Science][Medline]
17. Coller BS. Augmentation of thrombolysis with antiplatelet drugs. Overview. Coron Art Dis. 1996;6:911–914
18. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730–735[Web of Science][Medline]
19. Collet JP, Mirshahi M, Mishal Z, Montalescot G, Soria C, Soria J. A possible benefit of Reopro: modification of the clot structure. Thromb Haemost. 1997;June Suppl:662
20. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood. 1994;83:1006–1016[Abstract/Free Full Text]
21. Mascelli MA, Marciniak SJ, Weisman HF, Jordan R. In vitro characterization of dethrombosis by abciximab (Reopro). Thromb Haemost. 1997;June Suppl:661
22. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302–2306[Abstract/Free Full Text]
23. Ito H, Maruyama A, Iwakura K. Clinical implications of the ‘no reflow’ phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223–228[Abstract/Free Full Text]
24. Santoro GM, Valenti R, Buonamici P. Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty. Am J Cardiol. 1998;82:932–937[CrossRef][Web of Science][Medline]
25. van't Hof AWJ, de Boer M-J, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet. 1997;350:615–619[CrossRef][Web of Science][Medline]

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]

				W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF]

				V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]

				J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials Circulation, December 20, 2005; 112(25): 3855 - 3867. [Abstract] [Full Text] [PDF]

				G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]

				C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987. [Abstract] [Full Text] [PDF]

				M. Shimpo, D. A. Morrow, E. O. Weinberg, M. S. Sabatine, S. A. Murphy, E. M. Antman, and R. T. Lee Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction Circulation, May 11, 2004; 109(18): 2186 - 2190. [Abstract] [Full Text] [PDF]

				A. W.J van't Hof, N. Ernst, M.-J. de Boer, R. de Winter, E. Boersma, T. Bunt, S. Petronio, A.T Marcel Gosselink, W. Jap, F. Hollak, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial Eur. Heart J., May 2, 2004; 25(10): 837 - 846. [Abstract] [Full Text] [PDF]

				C. M. Gibson, J. Karha, S. A. Murphy, J. A. de Lemos, D. A. Morrow, R. P. Giugliano, M. T. Roe, R. A. Harrington, C. P. Cannon, E. M. Antman, et al. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1170 - 1176. [Abstract] [Full Text] [PDF]

				C. M. Gibson, D. S. Pinto, S. A. Murphy, D. A. Morrow, H.-P. Hobbach, S. D. Wiviott, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1535 - 1543. [Abstract] [Full Text] [PDF]

				S. Savonitto, P.W. Armstrong, A.M. Lincoff, G. Jia, C.A. Sila, J. Booth, P. Terrosu, C. Cavallini, H.D. White, D. Ardissino, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial Eur. Heart J., October 2, 2003; 24(20): 1807 - 1814. [Abstract] [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, R. Zhang, D. Morris, M. Lu, B. S. Coller, and M. Chopp Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke Circulation, June 10, 2003; 107(22): 2837 - 2843. [Abstract] [Full Text] [PDF]

				M. A Crouch, J. M Nappi, and K. I Cheang Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome Ann. Pharmacother., June 1, 2003; 37(6): 860 - 875. [Abstract] [Full Text] [PDF]

				R. P. Giugliano, M. T. Roe, R. A. Harrington, C. M. Gibson, U. Zeymer, F. Van de Werf, K. W. Baran, H.-P. Hobbach, L. H. Woodlief, K. L. Hannan, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1251 - 1260. [Abstract] [Full Text] [PDF]

				D. A. Morrow, E. M. Antman, A. Sayah, K. C. Schuhwerk, R. P. Giugliano, J. A. deLemos, M. Waller, S. A. Cohen, D. G. Rosenberg, S. S. Cutler, et al. Evaluation of the time saved byprehospital initiation of reteplase forST-elevation myocardial infarction: Results of the early retavase-thrombolysisin myocardial infarction (ER-TIMI) 19 trial J. Am. Coll. Cardiol., July 3, 2002; 40(1): 71 - 77. [Abstract] [Full Text] [PDF]

				E.M. Antman, H.A. Cooper, C.M. Gibson, J.A. de Lemos, C.H. McCabe, R.P. Giugliano, P. Coussement, S. Murphy, J. Scherer, K. Anderson, et al. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction. Insights from TIMI 14 and InTIME-II Eur. Heart J., June 2, 2002; 23(12): 928 - 933. [Abstract] [Full Text] [PDF]

				J. A. de Lemos and E. Braunwald ST segment resolution as a tool for assessing the efficacy of reperfusion therapy J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1283 - 1294. [Abstract] [Full Text] [PDF]

				J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]

				E.P. McFadden Fibrinolysis and stenting in acute myocardial infarction: newlyweds destined for a 'menage a trois'? Eur. Heart J., July 1, 2001; 22(13): 1067 - 1069. [PDF]

				F. Van de Werf New aspects of pharmacological reperfusion: from macro- to microlysis Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C62 - C68. [Abstract] [PDF]

				C. M. Gibson, J. A. de Lemos, S. A. Murphy, S. J. Marble, C. H. McCabe, C. P. Cannon, E. M. Antman, and E. Braunwald Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction : A TIMI 14 Substudy Circulation, May 29, 2001; 103(21): 2550 - 2554. [Abstract] [Full Text] [PDF]

				E. Braunwald Foreword Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A1 - A2. [PDF]

				A.M. Antman, J.A. de Lemos, and E. Braunwald Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A8 - A13. [Abstract] [PDF]

				P.W. Armstrong Reperfusion synergism: will it be both sustained and safe? Eur. Heart J., December 1, 2000; 21(23): 1913 - 1916. [PDF]

This Article Abstract FREE Full Text (PDF) E-letters: Submit a response Alert me when this article is cited Alert me when E-letters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (67) Request Permissions Disclaimer Google Scholar Articles by Antman, E.M Articles by Braunwald, E Search for Related Content PubMed PubMed Citation Articles by Antman, E.M Articles by Braunwald, E Social Bookmarking          What's this?

Online ISSN 1522-9645 - Print ISSN 0195-668x

Copyright © 2009 European Society of Cardiology

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics